The Definitive
Retatrutide Resource
Comprehensive, peer-reviewed knowledge base covering mechanism of action, clinical trials, safety data, and the latest research on the first triple GIP/GLP-1/glucagon receptor agonist.
New to Retatrutide?
What Is Retatrutide?
Understand the basics of this investigational triple-agonist peptide and why it matters.
Read article 02Mechanism of Action
Learn how retatrutide activates GLP-1, GIP, and glucagon receptors simultaneously.
Read article 03Safety Overview
Review the safety profile, common side effects, and tolerability data from clinical trials.
Read articleFeatured Knowledge
How to Get Retatrutide: Clinical Trials, Access, and Availability
Retatrutide is not approved as of 2026. Learn about clinical trial access, the TRIUMPH program, FDA approval timeline (2027-2028), and online safety risks.
Safety Profile of Retatrutide: Comprehensive Overview from Clinical Data
A thorough review of retatrutide's safety profile based on Phase 1, Phase 2, and Phase 3 TRIUMPH-4 clinical trial data, covering gastrointestinal adverse events, dysesthesia, laboratory findings, cardiovascular signals, hepatic effects, and outstanding safety questions.
What Is Retatrutide? A Comprehensive Overview of LY3437943
An in-depth introduction to retatrutide (LY3437943), the first-in-class triple GIP/GLP-1/glucagon receptor agonist in development by Eli Lilly for obesity and type 2 diabetes.
Explore Topics
Knowledge Base
In-depth articles on pharmacology, mechanism of action, safety, and outcomes.
Clinical Trials
Phase 2 and Phase 3 trial data, enrollment status, and key results.
Comparisons
Side-by-side analysis with semaglutide, tirzepatide, and other GLP-1 agonists.
Blog
Analysis, commentary, and updates on retatrutide research and development.
FAQ
Answers to the most common questions about retatrutide.
Glossary
Definitions of medical and scientific terms used across the knowledge base.
Trial Developments
Retatrutide Dose Escalation Optimization
Phase 3b Dosing Optimization Study for Retatrutide
Investigating different retatrutide dose escalation schemes to optimize efficacy-tolerability balance.
SYNERGY-OUTCOMES
SYNERGY-OUTCOMES: Retatrutide and Tirzepatide in MASLD/MASH
Master protocol evaluating both retatrutide and tirzepatide vs placebo for prevention of Major Adverse Liver Outcomes (MALO) in high-risk MASLD.
TRANSCEND-T2D-2
TRANSCEND-T2D-2: Retatrutide vs Semaglutide
Head-to-head comparison of retatrutide vs semaglutide in adults with T2D inadequately controlled on metformin +/- SGLT2 inhibitor.
Latest from the Blog
Next-Gen Obesity Drugs Compared: The 2026 Pipeline
Comparing retatrutide, orforglipron, amycretin, MariTide, survodutide, and VK2735 — mechanisms, efficacy data, and timelines as of April 2026.
Diet and Nutrition on Retatrutide: A Practical Guide
What to eat on retatrutide, how much protein you need, hydration strategies, and micronutrients to watch — based on clinical trial data.
Retatrutide Drug Interactions: What Clinicians Should Know
Analysis of potential retatrutide drug interactions based on GLP-1 class effects, including oral contraceptives, metformin, insulin, and anticoagulants.